$Pfizer(PFE.US) barely moved, $HENGRUI PHARMA(01276.HK) rose slightly. Pfizer is waiting for new products to ramp up volume to hedge against the patent cliff, while Hengrui's innovative drug overseas expansion and external licensing haven't reached the realization window yet. Both are quietly moving in a catalyst vacuum, with low volatility and no surprises 🙃
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
